Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of C$153.68M. The enterprise value is C$311.04M.
Market CapC$153.68M
Enterprise ValueC$311.04M
Share Statistics
HLS Therapeutics Inc has 31,557,089 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,557,089
Owned by Insiders0.47%
Owned by Institutions1.58%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -6.80%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-6.80%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee615.42K
Profits Per Employee-213.64K
Employee Count92
Asset Turnover0.35
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is -4.42. HLS Therapeutics Inc’s PEG ratio is -0.13.
PE Ratio-4.42
PS Ratio0.00
PB Ratio1.87
Price to Fair Value1.22
Price to FCF34.50
Price to Operating Cash Flow13.84
PEG Ratio-0.13
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of 56.62M and earned -19.66M in profits. Earnings per share was -0.62.
Revenue56.62M
Gross Profit47.62M
Operating Income-7.69M
Pretax Income-15.58M
Net Income-19.66M
EBITDA17.22M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was 10.77M and capital expenditures -34.00K, giving a free cash flow of 10.73M billion.
Operating Cash Flow10.77M
Free Cash Flow10.73M
Free Cash Flow per Share0.34
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of C$0.05, resulting in a dividend yield of ―
Dividend Per ShareC$0.05
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change40.87%
50-Day Moving Average4.80
200-Day Moving Average4.13
Relative Strength Index (RSI)47.60
Average Volume (3m)13.30K
Important Dates
HLS Therapeutics Inc upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend DateApr 27, 2023
Financial Position
HLS Therapeutics Inc as a current ratio of 1.57, with Debt / Equity ratio of 77.68%
Current Ratio1.57
Quick Ratio1.17
Debt to Market Cap0.75
Net Debt to EBITDA2.85
Interest Coverage Ratio-0.76
Taxes
In the past 12 months, HLS Therapeutics Inc has paid 4.07M in taxes.
Income Tax4.07M
Effective Tax Rate-0.26
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 7.90, with an EV/FCF ratio of 17.02.
EV to Sales2.40
EV to EBITDA7.90
EV to Free Cash Flow17.02
EV to Operating Cash Flow16.99
Balance Sheet
HLS Therapeutics Inc has C$17.73M in cash and marketable securities with $63.74M in debt, giving a net cash position of C$46.01M billion.
Cash & Marketable SecuritiesC$17.73M
Total Debt$63.74M
Net CashC$46.01M
Net Cash Per ShareC$1.46
Tangible Book Value Per Share-C$1.59
Margins
Gross margin is 91.90%, with operating margin of -13.57%, and net profit margin of -34.71%.
Gross Margin91.90%
Operating Margin-13.57%
Pretax Margin-27.52%
Net Profit Margin-34.71%
EBITDA Margin30.41%
EBIT Margin-9.71%
Analyst Forecast
The average price target for HLS Therapeutics Inc is C$7.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$7.25
Price Target Upside50.10% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-3.73%
EPS Growth Forecast32.70%